MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith Unaudited Financial Results of the Company for the third quarter ended 31st December, 2021 published on 12th February, 2022 in the Business Standard (English) and Tarun Bharat (Marathi) newspapers. MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Q3 FY22 earnings call. MARKSANS PHARMA LTD. - 524404 - Statement On Deviation Or Variation Of Funds Raised Through Preferential Issue Of Convertible Warrants
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMDl/162/2019 dated December 24, 2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June, 2021. Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended 31st December, 2021 is given in "Annexure A". Q3FY22 Quarterly Result Announced for Marksans Pharma Ltd.
Marksans Pharma declares Q3FY22 result: Operating Revenue was Rs 1,072.8 cr.; growth of 2.6 % as compared to Rs 1,046.0 Cr. in 9MFY21 EBITDA at Rs 195.2 cr. as compared to Rs 244.2 cr. in 9MFY21 EBITDA margins at 18.2% in 9MFY22 as against 23.3% in 9MFY21 PAT stood at Rs 157.2 Cr. as compared to Rs 159.2 Cr. in 9MFY21 EPS for 9MFY22 was Rs 3.82 compared to Rs 3.83 in 9MFY21 Result PDF MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached an investors presentation of Marksans Pharma Limited for Q3 & 9M FY22. MARKSANS PHARMA LTD. - 524404 - Unaudited Financial Results For The Third Quarter Ended 31St December, 2021 And Limited Review Reports Thereon.
In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results (both Standalone and Consolidated) for the third quarter ended 31st December, 2021 which have been approved by the Board of Directors at its meeting held today i.e. 11th February, 2022 along with Limited Review Reports given by Statutory auditor of the Company. The meeting commenced at 12:00 noon and concluded at 12:45 p.m. MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Notice Of Board Meeting
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 ,inter alia, to consider and approve Unaudited Financial Results of the Company (both Standalone and Consolidated) for the third Quarter ended 31st December, 2021. Please note that as per the Insider Trading Code of the Company, the Trading Window for dealing in Company''s shares has been closed for the Company''s Designated Persons from 1st January, 2022 and will remain closed till Forty-Eight hours after the announcement of the Financial Results on 11th February, 2022. MARKSANS PHARMA LTD. - 524404 - Shareholding for the Period Ended December 31, 2021
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2021 received from Bigshare Services Private Limited, Registrar and Transfer Agent of the Company. MARKSANS PHARMA LTD. - 524404 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Harshavardhan PanigrahiDesignation :- Company Secretary and Compliance Officer